Zachary Skrivanek

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Michael A. Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez et al. · Diabetes Care · 2014 · 273 citations · Full text

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes ( <scp>AWARD</scp> ‐5): a randomized, phase <scp>III</scp> study

Ruth S. Weinstock, Bruno Guerci, Guillermo E. Umpierrez et al. · Diabetes Obesity and Metabolism · 2015 · 145 citations · Full text

Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (<scp>AWARD</scp>‐5)

Zachary Skrivanek, Brenda Gaydos, Jenny Y. Chien et al. · Diabetes Obesity and Metabolism · 2014 · 62 citations · Full text

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

Helle Linnebjerg, Prajakti A. Kothare, Zachary Skrivanek et al. · Diabetic Medicine · 2006 · 48 citations

Exenatide effects on statin pharmacokinetics and lipid response

Prajakti A. Kothare, Helle Linnebjerg, Zachary Skrivanek et al. · International Journal of Clinical Pharmacology and Therapeutics · 2007 · 35 citations